Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKesson
Merck
Mallinckrodt
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAFINLAR

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Tafinlar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01940809 Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Recruiting National Cancer Institute (NCI) Phase 1 2013-08-01 This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether ipilimumab works better with or without dabrafenib, trametinib, and/or nivolumab in treating melanoma.
NCT02143050 Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting University of Louisville Phase 1/Phase 2 2014-09-01 The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.
NCT02143050 Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting James Graham Brown Cancer Center Phase 1/Phase 2 2014-09-01 The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.
NCT02231775 Neoadjuvant and Adjuvant Dabrafenib and Trametinib Compared to Upfront Surgery in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma (Combi-Neo) Active, not recruiting Novartis Pharmaceuticals Phase 2 2014-10-01 The goal of this clinical research study is to compare receiving the combination of dabrafenib and trametinib before surgery to having surgery alone in patients with melanoma. The safety of the study drug combination will also be studied.
NCT02231775 Neoadjuvant and Adjuvant Dabrafenib and Trametinib Compared to Upfront Surgery in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma (Combi-Neo) Active, not recruiting M.D. Anderson Cancer Center Phase 2 2014-10-01 The goal of this clinical research study is to compare receiving the combination of dabrafenib and trametinib before surgery to having surgery alone in patients with melanoma. The safety of the study drug combination will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafinlar

Condition Name

Condition Name for Tafinlar
Intervention Trials
Melanoma 12
Metastatic Melanoma 3
Anaplastic Pleomorphic Xanthoastrocytoma 2
Anaplastic Ganglioglioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tafinlar
Intervention Trials
Melanoma 16
Glioma 2
Glioblastoma 2
Ganglioglioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tafinlar

Trials by Country

Trials by Country for Tafinlar
Location Trials
United States 12
Germany 5
Netherlands 2
Belgium 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tafinlar
Location Trials
Massachusetts 5
Texas 3
Tennessee 1
Virginia 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tafinlar

Clinical Trial Phase

Clinical Trial Phase for Tafinlar
Clinical Trial Phase Trials
Phase 4 1
Phase 2 10
Phase 1/Phase 2 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tafinlar
Clinical Trial Phase Trials
Recruiting 14
Not yet recruiting 7
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tafinlar

Sponsor Name

Sponsor Name for Tafinlar
Sponsor Trials
National Cancer Institute (NCI) 5
Novartis 4
Massachusetts General Hospital 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tafinlar
Sponsor Trials
Other 26
Industry 16
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Baxter
Moodys
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.